Breaking Down RemeGen Co., Ltd. Financial Health: Key Insights for Investors

Dive into a data-driven look at RemeGen Co., Ltd. (9995.HK): nine‑month revenue through Sept 30, 2025 of RMB1.719 billion (up 42.3% y/y) and a trailing‑12‑month revenue of RMB2.23 billion (up 46.34% y/y) contrast with a nine‑month net loss of RMB550.70 million (improved from RMB1.071 billion), a TTM net profit margin of -85.53%, operating margin of -43.15%, and a market cap of RMB43.17 billion (P/S 19.38) as we unpack revenue momentum (Q1‑2025 revenue RMB621.88m, +33.13% y/y; 2024 revenue RMB1.72b, +58.54% y/y), profitability pressures (ROA -15.27%, ROE -56.64%, EPS -RMB1.01 for nine months), balance‑sheet dynamics (total liabilities RMB3.49b, total equity RMB2.36b, debt/equity 94.09%), cash and liquidity trends (cash & short‑term investments RMB1.28b, Q1‑2025 net cash change +RMB552.22m), and valuation signals (EV/Revenue 16.78, EV/EBITDA -29.92), so investors can weigh the risks and growth levers - read on for the full breakdown.

RemeGen Co., Ltd. (9995.HK) - Revenue Analysis

• Nine months ending Sep 30, 2025: revenue RMB1,719.0 million (↑42.3% vs. RMB1,208.0 million in 9M2024).
• TTM revenue as of Jun 2025: RMB2,230.0 million (↑46.34% YoY).
• Q1 2025 revenue: RMB621.88 million (↑33.13% YoY vs. Q1 2024).
• Full-year 2024 revenue: RMB1,720.0 million (↑58.54% vs. RMB1,080.0 million in 2023).
• Profitability: net loss of RMB550.70 million in 9M2025, improved from a loss of RMB1,071.0 million in 9M2024.
• Revenue per employee (TTM): ~RMB742,850 based on 2,999 employees and TTM revenue RMB2.23 billion.

• Rapid revenue growth (33-58% ranges across reported periods) suggests successful commercialization and increasing market penetration for core products.
• Despite higher sales, persistent net losses (RMB550.7m in 9M2025) indicate elevated R&D, SG&A, or commercialization costs; improving loss magnitude year-over-year signals operating leverage beginning to materialize.
• Revenue per employee (~RMB742,850) is a useful efficiency metric versus peers and highlights revenue density given headcount of 2,999.

RemeGen Co., Ltd. (9995.HK) - Profitability Metrics

• Net profit margin (TTM): -85.53% - indicates net losses amounting to the majority of revenue.
• Operating margin (TTM): -43.15% - operating expenses and cost structure are not covered by operating income.
• Return on assets (TTM): -15.27% - assets are generating negative returns.
• Return on equity (TTM): -56.64% - shareholders' equity has produced substantial negative returns.

• Profitability trajectory: year-over-year loss reduction (Q1 and 9M EPS improvements) suggests partial operational recovery, but TTM margins and returns remain far from break-even.
• Investor implications: negative ROE and ROA signal capital erosion; margin compression presents high risk for equity holders until consistent positive operating results emerge.

RemeGen Co., Ltd. (9995.HK) - Debt vs. Equity Structure

RemeGen's balance-sheet profile presents a capital structure tilted toward leverage by several measures, with recent volatility in cash flows and profitability amplifying investor focus on solvency and funding sources.

• Total debt-to-equity ratio: 94.09% (overall, indicating high leverage).
• Debt-to-equity ratio for 2023: 0.367 (moderate leverage in that year).
• Total liabilities (as of June 2025): RMB 3.49 billion - up 13.04% year-over-year.
• Total equity (as of June 2025): RMB 2.36 billion; Return on Equity (TTM): -56.64%.
• Net change in cash (Q1 2025): RMB 552.22 million - a 933.93% increase from the prior quarter.
• Market capitalization (as of Dec 18, 2025): ~RMB 43.17 billion; Price-to-Sales: 19.38.

Key considerations for investors:

• Leverage level: the near-1.0 aggregate debt-to-equity (94.09%) signals material creditor exposure relative to shareholder cushions; monitoring interest coverage and maturities is essential.
• Profitability drag: ROE (TTM) at -56.64% reflects losses eroding equity - raising importance of free cash generation and deleveraging paths.
• Liquidity dynamics: a strong sequential cash inflow in Q1 2025 (RMB 552.22 million, +933.93%) provides temporary relief but requires confirmation across subsequent quarters.
• Market pricing vs. fundamentals: market cap ~RMB 43.17 billion and P/S 19.38 imply high investor expectations relative to current equity and profitability metrics.

Further context on corporate strategy and long-term goals can be found here: Mission Statement, Vision, & Core Values (2026) of RemeGen Co., Ltd.

RemeGen Co., Ltd. (9995.HK) - Liquidity and Solvency

Key liquidity and solvency metrics for RemeGen Co., Ltd. through June 2025 show mixed signals: meaningful cash build and modest asset growth offset by rising liabilities, weakening short-term liquidity ratios, and a heavily negative profitability indicator that pressures solvency over the medium term.

• Cash & short-term investments (June 2025): RMB 1.28 billion (↑46.41% YoY)
• Quick ratio trend: 2.545 (2022) → 0.885 (Q1 2024), indicating a material deterioration in immediate liquidity
• Net change in cash (Q1 2025): RMB 552.22 million (↑933.93% QoQ)
• Total assets (June 2025): RMB 5.85 billion (↑1.67% YoY)
• Total liabilities (June 2025): RMB 3.49 billion (↑13.04% YoY)
• Net profit margin (TTM): -85.53%, reflecting substantial operating/financial losses relative to revenue

• Immediate liquidity: Cash cushion of RMB1.28bn and large QoQ cash inflow in Q1 2025 materially improve short-term cash posture despite a low quick ratio.
• Leverage and solvency pressure: Total liabilities grew 13.04% YoY to RMB3.49bn while assets only rose 1.67% YoY to RMB5.85bn - net asset coverage is narrowing.
• Profitability drag: TTM net profit margin at -85.53% erodes equity and raises refinancing risk if losses persist.
• Operational implications: The mismatch between improved cash balances and weak quick ratio suggests some assets classified outside quick assets (e.g., receivables, inventory) or timing effects from financing receipts.

For context on RemeGen's strategic direction and capital allocation priorities that affect liquidity decisions, see Mission Statement, Vision, & Core Values (2026) of RemeGen Co., Ltd.

RemeGen Co., Ltd. (9995.HK) - Valuation Analysis

• Market capitalization (as of 18 Dec 2025): RMB 43.17 billion
• Price-to-Sales (TTM): 19.38
• Price-to-Book (most recent quarter): 22.34
• Enterprise Value / Revenue: 16.78
• Enterprise Value / EBITDA: -29.92 (negative EBITDA)
• Return on Equity (TTM): -56.64%

• High PS and PB multiples indicate investor expectations of substantial future revenue and margin expansion; current negative EBITDA and ROE show those expectations are not yet realized.
• Negative EV/EBITDA means traditional profitability-based valuation comparisons are distorted; focus should shift to revenue growth trajectory, cash burn, and path to positive EBITDA.
• Given the premium valuation, downside risk from execution shortfalls is elevated while upside depends on delivering material operational improvement or breakthrough products.

RemeGen Co., Ltd. (9995.HK) - Risk Factors

• Net loss (9M 2025): RMB550.70 million vs. loss of RMB1.071 billion (9M 2024).
• Net profit margin (TTM): -85.53% - revenue covers only a small fraction of costs, producing a large negative margin.
• Operating margin (TTM): -43.15% - core operations remain unprofitable before non-operating items.
• Return on assets (TTM): -15.27% - asset base not generating positive returns.
• Return on equity (TTM): -56.64% - shareholders experiencing steep negative returns.
• Total liabilities (June 2025): RMB3.49 billion, up 13.04% YoY - rising leverage increases solvency risk.

• Liquidity risk: growing liabilities (RMB3.49 billion) may pressure cash flow and financing flexibility.
• Profitability risk: -85.53% net margin and -43.15% operating margin indicate recurring operating shortfalls.
• Capital efficiency risk: negative ROA (-15.27%) and ROE (-56.64%) signal value erosion for shareholders.
• Execution risk: converting narrowed losses into sustainable profitability requires meaningful cost control, revenue growth, or capital restructuring.

RemeGen Co., Ltd. (9995.HK) - Growth Opportunities

• Revenue acceleration: Q1 2025 revenue reached RMB621.88 million, up 33.13% year-over-year, showing continued commercialization traction.
• Full-year expansion: 2024 revenue was RMB1.72 billion, a 58.54% increase from RMB1.08 billion in 2023, reflecting portfolio growth and higher product sales.
• High market valuation: Market cap (as of 18 Dec 2025) ~RMB43.17 billion, implying elevated expectations for future cash flows and pipeline success.
• Profitability gap: Negative EBITDA (EV/EBITDA of -29.92) and ROE (TTM) of -56.64% point to ongoing operating losses and equity dilution or accumulated deficits.

• Growth drivers: commercial rollouts, expanded indications, licensing/partnership deals, and potential new product launches can sustain revenue growth and justify premium multiples.
• Key risks: continued negative EBITDA, heavy R&D or SG&A spend, need for external financing, and valuation sensitivity to pipeline setbacks.
• Investor considerations: monitor quarterly revenue cadence, margin expansion, progress toward positive EBITDA, and equity changes that affect ROE.